Vical Incorporated - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Vical Incorporated - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Vical Incorporated - Product Pipeline Review - 2014', provides an overview of the Vical Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Vical Incorporated including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vical Incorporated's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Vical Incorporated's pipeline products

Reasons to buy

- Evaluate Vical Incorporated's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vical Incorporated in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vical Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vical Incorporated and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vical Incorporated
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Vical Incorporated Snapshot 5
Vical Incorporated Overview 5
Key Information 5
Key Facts 5
Vical Incorporated - Research and Development Overview 6
Key Therapeutic Areas 6
Vical Incorporated - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Vical Incorporated - Pipeline Products Glance 14
Vical Incorporated - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Vical Incorporated - Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
Vical Incorporated - Early Stage Pipeline Products 16
IND/CTA Filed Products/Combination Treatment Modalities 16
Preclinical Products/Combination Treatment Modalities 17
Vical Incorporated - Drug Profiles 18
velimogene aliplasmid 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
HSV-2 Vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
VCLHB-01 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
VCLHM-01 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CyMVectin 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Vaxfectin Formulated TRP2 Vaccine for Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vaxfectin-Formulated Measles DNA Vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Vical Incorporated - Pipeline Analysis 29
Vical Incorporated - Pipeline Products by Target 29
Vical Incorporated - Pipeline Products by Route of Administration 30
Vical Incorporated - Pipeline Products by Molecule Type 31
Vical Incorporated - Pipeline Products by Mechanism of Action 32
Vical Incorporated - Recent Pipeline Updates 33
Vical Incorporated - Dormant Projects 37
Vical Incorporated - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
HIV Vaccine 38
velimogene aliplasmid 38
Vical Incorporated - Company Statement 39
Vical Incorporated - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Vical Incorporated, Key Information 5
Vical Incorporated, Key Facts 5
Vical Incorporated - Pipeline by Indication, 2014 7
Vical Incorporated - Pipeline by Stage of Development, 2014 8
Vical Incorporated - Monotherapy Products in Pipeline, 2014 9
Vical Incorporated - Partnered Products in Pipeline, 2014 10
Vical Incorporated - Partnered Products/ Combination Treatment Modalities, 2014 11
Vical Incorporated - Out-Licensed Products in Pipeline, 2014 12
Vical Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Vical Incorporated - Phase III, 2014 14
Vical Incorporated - Phase I, 2014 15
Vical Incorporated - IND/CTA Filed, 2014 16
Vical Incorporated - Preclinical, 2014 17
Vical Incorporated - Pipeline by Target, 2014 29
Vical Incorporated - Pipeline by Route of Administration, 2014 30
Vical Incorporated - Pipeline by Molecule Type, 2014 31
Vical Incorporated - Pipeline Products by Mechanism of Action, 2014 32
Vical Incorporated - Recent Pipeline Updates, 2014 33
Vical Incorporated - Dormant Developmental Projects,2014 37
Vical Incorporated - Discontinued Pipeline Products, 2014 38